Phase 3 study comparing the efficacy and safety of proposed biosimilar RGB-14-P with denosumab in postmenopausal women with osteoporosis: results from the transition (switch) phase
Summary Osteoporosis is a chronic condition requiring long-term management of fracture risk. Biosimilars provide the possibility of continuous use of well-established compounds. Proposed denosumab biosimilar RGB-14-P demonstrated equivalent efficacy and similar pharmacodynamics,…